<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23613">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799381</url>
  </required_header>
  <id_info>
    <org_study_id>M15-535</org_study_id>
    <secondary_id>2016-001403-23</secondary_id>
    <nct_id>NCT02799381</nct_id>
  </id_info>
  <brief_title>An Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease</brief_title>
  <acronym>DYSCOVER</acronym>
  <official_title>An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to examine the effect of levodopa-carbidopa
      intestinal gel (LCIG) compared with optimized medical treatment (OMT) on dyskinesia in
      participants with advanced Parkinson's disease (PD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Unified Dyskinesia Rating Scale (UDysRS) Total Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The UDysRS is used to evaluate on-dyskinesia in Parkinson's disease and the impact of on-dyskinesia on experiences of daily living.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ON time without troublesome dyskinesia</measure>
    <time_frame>12 weeks</time_frame>
    <description>&quot;ON&quot; time without troublesome dyskinesia as measured by the Parkinson's disease Diary, which the subject and/or caregiver uses to record Parkinsonian symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionaire-8 (PDQ-8) Summary Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>The PDQ-8 is a self-administered questionnaire that measures aspects of health that are relevant to subjects with PD that may not be included in general health status questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression of Change (CGI-C) Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>The CGI-C is a rating scale for assessing Global Improvement or Change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score (Activities of Daily Living)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The UPDRS is a rating tool to follow the longitudinal course of Parkinson's disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OFF time</measure>
    <time_frame>12 weeks</time_frame>
    <description>OFF time as measured by Parkinson's disease Diary, which the subject and/or caregiver uses to record Parkinsonian symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score (Motor Examination)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The UPDRS is a rating tool to follow the longitudinal course of Parkinson's disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>ABT-SLV187</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 Week Period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 Week Period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-SLV187</intervention_name>
    <description>Dose levels will be individually optimized.</description>
    <arm_group_label>ABT-SLV187</arm_group_label>
    <other_name>Carbidopa-Levodopa Enteral Suspension</other_name>
    <other_name>LCIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>optimized antiparkinsonian treatment</intervention_name>
    <description>Dose levels of prescribed antiparkinsonian medications will be individually optimized to their maximum therapeutic effect.</description>
    <arm_group_label>Optimized Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have a diagnosis of idiopathic Parkinson's disease (PD )according
             to the United Kingdom Parkinson's Disease Society (UKPDS) Brain Bank Criteria

          -  Participants with advanced levodopa-responsive PD and persistent motor fluctuations
             who have not been controlled with optimized medical treatment (OMT: the maximum
             therapeutic effect obtained with pharmacological antiparkinsonian therapies when no
             further improvement is expected with regard to any additional manipulations of
             levodopa and/or other antiparkinsonian medication based on the Investigator's
             clinical judgment)

          -  Unified Dyskinesia Rating Scale (UDysRs) Total score â‰¥ 30 at Visit 3

        Exclusion Criteria:

          -  Patient(s) treated with LCIG previously

          -  Patient's PD diagnosis is unclear or there is a suspicion that the subject has a
             parkinsonian syndrome such as secondary parkinsonism (e.g. caused by drugs, toxins,
             infectious agents, vascular disease, trauma, brain neoplasm), parkinson-plus syndrome
             (e.g. Multiple System Atrophy, Progressive supranuclear Palsy, Diffuse Lewy Body
             disease) or other neurodegenerative disease that might mimic the symptoms of PD

          -  Patient(s) has undergone neurosurgery for the treatment of Parkinson's disease.

          -  Patient(s) has contraindications to levodopa (e.g. narrow angle glaucoma, malignant
             melanoma)

          -  Patient(s) experiencing clinically significant sleep attacks or clinically
             significant impulsive behavior (e.g. pathological gambling, hypersexuality) at any
             point during the three months prior to the Screening evaluation as judged by the
             Principal Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lou Barbato, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150095</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150095, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150093</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150093, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150088</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150088, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150955</name>
      <address>
        <city>Glyfada</city>
        <zip>16675</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150955, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150851</name>
      <address>
        <city>Naples</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150851, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151167</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151167, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150846</name>
      <address>
        <city>Rome</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150846, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150171</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150171, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150144</name>
      <address>
        <city>Bratislava</city>
        <zip>833 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150144, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150145</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150145, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150154</name>
      <address>
        <city>Elche, Alicante</city>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150154, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150157</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150157, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150155</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150155, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 150152</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 150152, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>Italy</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 14, 2017</lastchanged_date>
  <firstreceived_date>June 10, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>carbidopa</keyword>
  <keyword>levodopa</keyword>
  <keyword>levodopa-carbidopa intestinal gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Antiparkinson Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
